MedTrace Logo

Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes

NCT00541606 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2009-05-19

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that pharmacists working collaboratively with physicians and other providers in an ambulatory care setting can improve glucose, blood pressure, and lipid control, as well as improve quality of life, adherence to screening and general preventative measures.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

OTHER

Pharmacist collaboration in diabetes care

Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.

OTHER

Usual care

Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Lahey Clinic

    lead OTHER

Principal Investigators

  • Gary Cushing, MD · Lahey Clinic, Burlington, MA

  • Michelle Jacobs, PharmD · Currently: Northeastern University, Boston, MA

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Completion
2004-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00541606 on ClinicalTrials.gov